The groundbreaking medication, Mounjaro, is creating considerable excitement within the healthcare community as a potential option for managing Non-Insulin-Dependent Glucose Intolerance . Unlike some traditional approaches, Mounjaro utilizes a dual action , targeting both GLP-1 receptors and the